Financial Comparison: Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) & Icosavax (NASDAQ:ICVX)

Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) and Icosavax (NASDAQ:ICVX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Eupraxia Pharmaceuticals and Icosavax’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	N/A	N/A
Icosavax	N/A	-43.06%	-39.53%

Earnings & Valuation

This table compares Eupraxia Pharmaceuticals and Icosavax’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Icosavax	$580,000.00	1,322.20	-$91.76 million	($2.22)	-6.90

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Icosavax.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Eupraxia Pharmaceuticals and Icosavax, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	0	0	0	1	4.00
Icosavax	0	2	1	0	2.33

Eupraxia Pharmaceuticals currently has a consensus price target of C$18.00, indicating a potential upside of 587.02%. Icosavax has a consensus price target of $26.50, indicating a potential upside of 73.09%. Given Eupraxia Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Icosavax.

Insider & Institutional Ownership

92.6% of Icosavax shares are owned by institutional investors. 30.6% of Icosavax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Eupraxia Pharmaceuticals beats Icosavax on 5 of the 9 factors compared between the two stocks.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

About Icosavax

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.